The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. This combination targets the GPRC5D protein on myeloma cells, showing significant improvements in progression-free survival (up to 81%) and overall survival (up to 89%) at 24 months in a Phase 3 study. If approved, this therapy would offer a novel immunotherapy option that preserves healthy immune cells and could provide deeper, longer-lasting responses for patients. Johnson & Johnson aims to expand treatment options and improve outcomes by introducing this combination earlier in the disease course.
Johnson & Johnson shares are currently priced at USD 262.85 on Pluang, down 1.78% in the past day, with a market cap of $644.22 billion. As of Oct 24, 2026 01:11 WIB, the stock sees more selling pressure with 78% of order activity as Sell and a typical hold time of 129 days.
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
More than 200 companies are actively developing over 240 Alzheimer's disease therapies, with around 20 drugs in late-stage trials and many others in earlier phases. Key players include Eli Lilly, Biogen, Johnson & Johnson, and Eisai, focusing on inno...
Procter & Gamble's stock surged 6% following a quarterly earnings beat with core EPS of $2 and net sales of $23.28 billion, surpassing expectations. The company’s price increases are holding up well, driven by resilient higher-income consumers, thoug...
Johnson & Johnson reported strong pharmaceutical growth with Innovative Medicine up 7.9%, driving optimism for its stock with a 12-month price target of $288.66, an 11.48% upside. However, its MedTech segment showed weak international sales growth an...
Johnson & Johnson has increased its dividend annually for 64 years, yet its stock returns over the past decade were outpaced by the S&P 500 index. While a $1,000 investment in J&J grew to about $2,957 with dividends reinvested, the S&P 500 grew even ...
